Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401178 | 0.83 | HSD17B10 (0.49) | HSD17B10HPGDATMEPHX1SMN1; SMN2 | |
| SCHEMBL1648263 | 0.83 | ATM (0.41) | HSD17B10HPGDATMCHRM2CHRM1 | |
| SCHEMBL20522096 | 0.83 | HSD17B10 (0.49) | HSD17B10HPGDATMEPHX1SMN1; SMN2 | |
| SCHEMBL30344858 | 0.81 | HSD17B10 (0.40) | HSD17B10HPGDATMRECQLCHRM2 | |
| SCHEMBL24121385 | 0.80 | ATM (0.42) | HSD17B10HPGDATMRECQLCHRM2 | |
| SCHEMBL71904 | 0.80 | NR1H2 (0.45) | HSD17B10HPGDATMCHRM2CHRM1 | |
| SCHEMBL8073389 | 0.80 | HSD17B10 (0.41) | HSD17B10HPGDATMRECQLEPHX1 | |
| SCHEMBL19158003 | 0.80 | ATM (0.42) | HSD17B10HPGDATMRECQLCHRM2 | |
| SCHEMBL4967116 | 0.80 | HSD17B10 (0.41) | HSD17B10HPGDATMRECQLEPHX1 | |
| SCHEMBL283443 | 0.80 | NR1H2 (0.45) | HSD17B10HPGDATMCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118574834-A | Fused tetracyclic compounds, compositions and uses thereof | 泰博生物科技股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4274833-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150707-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | HSD17B10 1402/4885HPGD 201/4885ATM 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.